Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease

Molecular Genetics and Metabolism

Volumn 111, Issue 2, 2014, Pages 184-192

  Labilloy, Anatália ^a,b,c   Youker, Robert T ^a   Bruns, Jennifer R ^a   Kukic, Ira ^b   Kiselyov, Kirill ^b   Halfter, Willi ^d   Finegold, David ^b   Monte, Semiramis Jamil Hadad do ^a   Weisz, Ora A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Federal University of Piauí ^*  (Brazil)

^d FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

Author keywords

Fabry disease; GPI anchored proteins; Kidney; Lipid rafts; Number and brightness analysis; Polarized sorting

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; GLYCOSYLPHOSPHATIDYLINOSITOL; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FABRY DISEASE; GENE SILENCING; KIDNEY TUBULE CELL; LIPID RAFT; LIPID STORAGE; LYSOSOME; MDCK CELL; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZEBRA BODY;

EQUUS SUBG. HIPPOTIGRIS;

DIPEPTIDYLPEPTIDASE IV; DPPIV; EARLY ENDOSOMAL ANTIGEN 1; EEA1; ENZYME REPLACEMENT THERAPY; ERT; FABRY DISEASE; GB3; GLOBOTRIAOSYLCERAMIDE; GLYCOSYLPHOSPHATIDYLINOSITOL; GPI; GPI-ANCHORED PROTEINS; HA; HEMAGGLUTININ; KIDNEY; LAMP-2; LIPID RAFTS; LSD; LYSOSOMAL MEMBRANE ASSOCIATED PROTEIN 2; LYSOSOMAL STORAGE DISORDER; MADIN-DARBY CANINE KIDNEY; MDCK; N&B; NUMBER AND BRIGHTNESS; NUMBER AND BRIGHTNESS ANALYSIS; POLARIZED SORTING; QRT-PCR; REAL-TIME QUANTITATIVE REVERSE-TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RT-PCR; Α-GAL A; Α-GALACTOSIDASE A;

ALPHA-GALACTOSIDASE; ANIMALS; DOGS; FABRY DISEASE; GENE EXPRESSION; GLYCOSYLPHOSPHATIDYLINOSITOLS; GREEN FLUORESCENT PROTEINS; HUMANS; KIDNEY; LYSOSOMES; MADIN DARBY CANINE KIDNEY CELLS; MEMBRANE MICRODOMAINS; MODELS, BIOLOGICAL; RNA, SMALL INTERFERING; TRIHEXOSYLCERAMIDES;

EID: 84893653432     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.10.010     Document Type: Article

References (74)

1. Yoshimitsu M., et al. Identification of novel mutations in the alpha-galactosidase A gene in patients with Fabry disease: pitfalls of mutation analyses in patients with low alpha-galactosidase A activity. J. Cardiol. 2011, 57(3):345-353.
2. Germain D.P. Fabry disease. Orphanet J. Rare Dis. 2010, 5:30.
3. Alpha-galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease 2001, 3733-3774. McGraw-Hill, New York. 8th ed. R.J. Desnick, Y.A. Ioannou, C.M. Eng (Eds.).
4. Eng C.M., et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J. Inherit. Metab. Dis. 2007, 30(2):184-192.
5. Ortiz A., et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol. Dial. Transplant. 2010, 25(3):769-775.
6. Pintos-Morell G., Beck M. Fabry disease in children and the effects of enzyme replacement treatment. Eur. J. Pediatr. 2009, 168(11):1355-1363.
7. Hopkin R.J., et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr. Res. 2008, 64(5):550-555.
8. Tondel C., et al. Agalsidase benefits renal histology in young patients with Fabry disease. J. Am. Soc. Nephrol. 2013, 24(1):137-148.
9. Fogo A.B., et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol. Dial. Transplant. 2010, 25(7):2168-2177.
10. Watt T., et al. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet. Med. 2010, 12(11):703-712.
11. Wilcox W.R., et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 2004, 75(1):65-74.
12. Hughes D.A., et al. A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease. Mol. Genet. Metab. 2013, 109(3):269-275.
13. Weidemann F., et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J. Intern. Med. 2013, 274(4):331-341.
14. Feriozzi S., et al. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin. J. Am. Soc. Nephrol. 2012, 7(1):60-69.
15. Warnock D.G., et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol. Dial. Transplant. 2012, 27(3):1042-1049.
16. Lannert H., et al. Functional organization of the Golgi apparatus in glycosphingolipid biosynthesis. Lactosylceramide and subsequent glycosphingolipids are formed in the lumen of the late Golgi. J. Biol. Chem. 1998, 273(5):2939-2946.
17. Keusch J.J., et al. Cloning of Gb3 synthase, the key enzyme in globo-series glycosphingolipid synthesis, predicts a family of alpha 1, 4-glycosyltransferases conserved in plants, insects, and mammals. J. Biol. Chem. 2000, 275(33):25315-25321.
18. Nutikka A., Lingwood C. Generation of receptor-active, globotriaosyl ceramide/cholesterol lipid 'rafts' in vitro: a new assay to define factors affecting glycosphingolipid receptor activity. Glycoconj. J. 2004, 20(1):33-38.
19. Lingwood D., Simons K. Lipid rafts as a membrane-organizing principle. Science 2010, 327(5961):46-50.
20. Melkonian K.A., et al. Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts. Many raft proteins are acylated, while few are prenylated. J. Biol. Chem. 1999, 274(6):3910-3917.
21. Delacour D., et al. Galectin-4 and sulfatides in apical membrane trafficking in enterocyte-like cells. J. Cell Biol. 2005, 169(3):491-501.
22. Owen D.M., et al. The lipid raft hypothesis revisited-new insights on raft composition and function from super-resolution fluorescence microscopy. Bioessays 2012, 34(9):739-747.
23. Wang R., et al. Lipid raft regulates the initial spreading of melanoma A375 cells by modulating beta1 integrin clustering. Int. J. Biochem. Cell Biol. 2013, 45(8):1679-1689.
24. Simons K., Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 2000, 1(1):31-39.
25. Fullekrug J., Simons K. Lipid rafts and apical membrane traffic. Ann. N. Y. Acad. Sci. 2004, 1014:164-169.
26. Weisz O.A., Rodriguez-Boulan E. Apical trafficking in epithelial cells: signals, clusters and motors. J. Cell Sci. 2009, 122(Pt 23):4253-4266.
27. Schuck S., Simons K. Polarized sorting in epithelial cells: raft clustering and the biogenesis of the apical membrane. J. Cell Sci. 2004, 117(Pt 25):5955-5964.
28. Paladino S., et al. Protein oligomerization modulates raft partitioning and apical sorting of GPI-anchored proteins. J. Cell Biol. 2004, 167(4):699-709.
29. Galmes R., et al. Oligomerization is required for normal endocytosis/transcytosis of a GPI-anchored protein in polarized hepatic cells. J. Cell Sci. 2013, 126(Pt 15):3409-3416.
30. Shi D., et al. Smoothened oligomerization/higher order clustering in lipid rafts is essential for high hedgehog activity transduction. J. Biol. Chem. 2013, 288(18):12605-12614.
31. Lemaire-Ewing S., Lagrost L., Neel D. Lipid rafts: a signalling platform linking lipoprotein metabolism to atherogenesis. Atherosclerosis 2012, 221(2):303-310.
32. Ehehalt R., et al. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 2003, 160(1):113-123.
33. Kosicek M., et al. Cholesterol accumulation in Niemann Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts. Biochem. Biophys. Res. Commun. 2010, 393(3):404-409.
34. Langeveld M., et al. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J. Clin. Endocrinol. Metab. 2008, 93(3):845-851.
35. te Vruchte D., et al. Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice. J. Inherit. Metab. Dis. 2010, 33(3):261-270.
36. Dawson G., et al. Abnormal gangliosides are localized in lipid rafts in Sanfilippo (MPS3a) mouse brain. Neurochem. Res. 2012, 37(6):1372-1380.
37. Rusyn E., et al. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content. Pediatr. Res. 2008, 63(6):625-631.
38. White A.B., et al. Persistence of psychosine in brain lipid rafts is a limiting factor in the therapeutic recovery of a mouse model for Krabbe disease. J. Neurosci. Res. 2011, 89(3):352-364.
39. Maalouf K., et al. A modified lipid composition in Fabry disease leads to an intracellular block of the detergent-resistant membrane-associated dipeptidyl peptidase IV. J. Inherit. Metab. Dis. 2010, 33(4):445-449.
40. Chen C.S., et al. Broad screening test for sphingolipid-storage diseases. Lancet 1999, 354(9182):901-905.
41. Simons K., Vaz W.L. Model systems, lipid rafts, and cell membranes. Annu. Rev. Biophys. Biomol. Struct. 2004, 33:269-295.
42. Digman M.A., et al. Mapping the number of molecules and brightness in the laser scanning microscope. Biophys. J. 2008, 94(6):2320-2332.
43. Crosby K.C., et al. Quantitative analysis of self-association and mobility of annexin A4 at the plasma membrane. Biophys. J. 2013, 104(9):1875-1885.
44. Hellriegel C., et al. Number and brightness image analysis reveals ATF-induced dimerization kinetics of uPAR in the cell membrane. FASEB J. 2011, 25(9):2883-2897.
45. Herrick-Davis K., et al. Oligomer size of the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor revealed by fluorescence correlation spectroscopy with photon counting histogram analysis: evidence for homodimers without monomers or tetramers. J. Biol. Chem. 2012, 287(28):23604-23614.
46. Henkel J.R., et al. Selective perturbation of apical membrane traffic by expression of influenza M2, an acid-activated ion channel, in polarized Madin-Darby canine kidney cells. Mol. Biol. Cell 1998, 9(9):2477-2490.
47. Youker R.T., et al. Multiple motifs regulate apical sorting of p75 via a mechanism that involves dimerization and higher-order oligomerization. Mol. Biol. Cell 2013, 24(12):1996-2007.
48. Ohshima T., et al. Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(6):2540-2544.
49. Liebau M.C., et al. Dysregulated autophagy contributes to podocyte damage in Fabry's disease. PLoS ONE 2013, 8(5):e63506.
50. Thomaidis T., et al. Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy. Kidney Int. 2009, 75(4):399-407.
51. Namdar M., et al. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. PLoS ONE 2012, 7(4):e36373.
52. Medin J.A., et al. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(15):7917-7922.
53. Askari H., et al. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch. 2007, 451(4):823-834.
54. Yam G.H., et al. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. Am. J. Physiol. Cell Physiol. 2006, 290(4):C1076-C1082.
55. Alroy J., Sabnis S., Kopp J.B. Renal pathology in Fabry disease. J. Am. Soc. Nephrol. 2002, 13(Suppl. 2):S134-S138.
56. Ikonen E. Roles of lipid rafts in membrane transport. Curr. Opin. Cell Biol. 2001, 13(4):470-477.
57. Glebov O.O., Nichols B.J. Distribution of lipid raft markers in live cells. Biochem. Soc. Trans. 2004, 32(Pt 5):673-675.
58. Nohe A., et al. Dynamics of GPI-anchored proteins on the surface of living cells. Nanomedicine 2006, 2(1):1-7.
59. Suzuki K.G., et al. GPI-anchored receptor clusters transiently recruit Lyn and G alpha for temporary cluster immobilization and Lyn activation: single-molecule tracking study 1. J. Cell Biol. 2007, 177(4):717-730.
60. Legewie S., et al. Recurrent design patterns in the feedback regulation of the mammalian signalling network. Mol. Syst. Biol. 2008, 4:190.
61. Suzuki K.G., et al. Transient GPI-anchored protein homodimers are units for raft organization and function. Nat. Chem. Biol. 2012, 8(9):774-783.
62. Friedrichson T., Kurzchalia T.V. Microdomains of GPI-anchored proteins in living cells revealed by crosslinking. Nature 1998, 394(6695):802-805.
63. Hofman E.G., et al. EGF induces coalescence of different lipid rafts. J. Cell Sci. 2008, 121(Pt 15):2519-2528.
64. Horejsi V., et al. Signal transduction in leucocytes via GPI-anchored proteins: an experimental artefact or an aspect of immunoreceptor function?. Immunol. Lett. 1998, 63(2):63-73.
65. Potter B.A., et al. Specific N-glycans direct apical delivery of transmembrane, but not soluble or glycosylphosphatidylinositol-anchored forms of endolyn in Madin-Darby canine kidney cells. Mol. Biol. Cell 2004, 15(3):1407-1416.
66. Simons K., Ehehalt R. Cholesterol, lipid rafts, and disease. J. Clin. Invest. 2002, 110(5):597-603.
67. Cheng P.C., et al. Translocation of the B cell antigen receptor into lipid rafts reveals a novel step in signaling. J. Immunol. 2001, 166(6):3693-3701.
68. Hern J.A., et al. Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(6):2693-2698.
69. Kasai R.S., et al. Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. J. Cell Biol. 2011, 192(3):463-480.
70. Calebiro D., et al. Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(2):743-748.
71. 2+ signaling: single-molecule tracking study 2. J. Cell Biol. 2007, 177(4):731-742.
72. Finger E.C., et al. Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. J. Biol. Chem. 2008, 283(50):34808-34818.
73. Di Guglielmo G.M., et al. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat. Cell Biol. 2003, 5(5):410-421.
74. Sanchez-Nino M.D., et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol. Dial. Transplant. 2011, 26(6):1797-1802.